Medicaid Add-On Rebates For Line Extensions Remain A Judgment Call
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturers must continue to use their discretion on which line extensions should be subject to inflation-based Medicaid rebates in lieu of guidance from CMS in its recent AMP final rule.
You may also be interested in...
What Is A ‘Line Extension’? Medicaid Tries Again With Sweeping Definition
In the latest reminder of how badly industry lost the argument over the value of incremental improvements in formulations, US is proposing enhanced Medicaid rebates on virtually all new formulations of existing brands.
Medicaid Inflation Rebates Would Apply To More Products Under Line Extension Proposal
Proposed rule also addresses impact of copay ‘accumulator’ programs on reporting Medicaid best prices and lays out more stringent requirements for manufacturers to be able to exclude such assistance from calculations.
Medicaid Rebates To Increase $3.95bn With Revision For Line Extensions
CMS issues interim final rule to ensure there’s ‘no confusion’ that line extensions are now subject to higher Medicaid rebate requirements.